AMDL, Inc. (Amex: ADL), (), a leader in specialty pharmaceuticals, announced today its subsidiary Jade Pharmaceutical, Inc. (JPI) anticipates releasing during the 3rd quarter of 2008 two new formulations of its popular Goodnak(R) anti-aging skin care product line. In addition to its high quality injectable formulation, JPI anticipates offering Goodnak in capsules and an easy-to-apply lotion.

Based on general market information, the proposed pricing for these new formulations will be approximately US$40.00 per unit, with 60% gross profit margins. JPI plans to sell both products through existing distribution channels within the Henan, Sichuan, Guizhou, Shanxi, Xinjiang, Gansu, Hunnan, Zhejiang, Fujian, Liaoning and Heilongjiang Provinces of China. Together these regions have a combined population of more than 376 million people. In addition to China, AMDL believes both products will be good candidates for export to the North American and European markets.

According to Gary Dreher, CEO of AMDL, "With the popularity of the Goodnak brand in China, combined with JPI's ability to sell through pre-approved distribution channels, we anticipate sales to exceed well beyond our initial annual sales forecast for Goodnak of $24 million. This is extremely positive news for the market, Company and our shareholders."

Additional information on AMDL, Goodnak and the Company's other pharmaceutical products is available at .

About AMDL:

AMDL, Inc. is a global specialty pharmaceutical Company. The Company is headquartered in Tustin, California with operations in Shenzhen, Jiangxi, and Jilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDL is devoted to the research, development, manufacture, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in China. The Company employs approximately 320 people in the U.S. and China.

About Jade Pharmaceutical:

JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact: Kristine Szarkowitz
206.310.5323